Northeast Pharmaceutical Group Gestione

Gestione criteri di controllo 2/4

Northeast Pharmaceutical Group Il CEO è Zhou Kai, nominato in May2019, ha un mandato di 5.5 anni. possiede direttamente 0.3% delle azioni della società, per un valore di CN¥ 21.94M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.3 anni e 5 anni.

Informazioni chiave

Zhou Kai

Amministratore delegato

CN¥1.8m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	5.5yrs
Proprietà del CEO	0.3%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Zhou Kai (60 yo)

5.5yrs

Mandato

CN¥1,824,100

Compensazione

Mr. Zhou Kai serves as a General Manager of Northeast Pharmaceutical Group Co., Ltd. since May 8, 2019 and serves its Non-Independent Director since November 29, 2020. He served as a Vice President of Nort...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Zhou Kai	GM & Director	5.5yrs	CN¥1.82m	0.30% CN¥ 21.9m
Jialun Song	Financial Director & Secretary	1.8yrs	CN¥2.14m	0.022% CN¥ 1.7m
Xiao Feng	Deputy General Manager	less than a year	CN¥894.30k	Nessun dato
Yonggang Cai	Deputy General Manager	less than a year	Nessun dato	Nessun dato

1.3yrs

Durata media

51.5yo

Età media

Gestione esperta: Il team dirigenziale di 000597 non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Zhou Kai	GM & Director	4yrs	CN¥1.82m	0.30% CN¥ 21.9m
Demin Han	Independent Director	6.3yrs	CN¥150.00k	Nessun dato
Zhaochun Tan	Non-Independent Director	3yrs	Nessun dato	Nessun dato
Chengren Huang	Non-Independent Director	6.3yrs	Nessun dato	0.23% CN¥ 16.7m
Xinhua Ao	Non-Independent Director	6.3yrs	Nessun dato	0.23% CN¥ 16.7m
Guodong Wang	Independent Director	6.3yrs	CN¥150.00k	Nessun dato
Hui Yao	Independent Director	6.3yrs	CN¥150.00k	Nessun dato
Youguang Shang	Independent Director	4.1yrs	CN¥150.00k	Nessun dato
Jianmin Guo	Chairman of the Board	3.1yrs	CN¥2.07m	0.22% CN¥ 16.6m
Zhihua Huang	Non-Independent Director	3yrs	Nessun dato	0.070% CN¥ 5.2m
Baidan Zhan	Chairman of the Supervisory Board	5.9yrs	Nessun dato	Nessun dato
Hai Tian	Director	1.2yrs	Nessun dato	Nessun dato

5.0yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 000597 sono considerati esperti (durata media dell'incarico 5 anni).

Northeast Pharmaceutical Group Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Recent updates

Now 21% undervalued

Investor sentiment improves as stock rises 22%

Third quarter 2024 earnings released: EPS: CN¥0.036 (vs CN¥0.059 in 3Q 2023)

Investor sentiment improves as stock rises 19%

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.045 in 2Q 2023)

Investor sentiment deteriorates as stock falls 22%

New minor risk - Share price stability

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Dividend of CN¥0.10 announced

Northeast Pharmaceutical Group Co., Ltd. Implements 2023 Final Cash Profit Distribution Plan, Payable on 23 May 2024

New minor risk - Earnings quality

First quarter 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.049 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in FY 2022)

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment deteriorates as stock falls 18%

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

High number of new directors

Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.033 in 2Q 2022)

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. Announces 2022 Final Cash Profit Distribution Plan, Payable on 16 May 2023

Full year 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.07 in FY 2021)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.026 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.016 in 2Q 2021)

High number of new directors

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2021, Payable on 27 May 2022

First quarter 2022 earnings released: EPS: CN¥0.051 (vs CN¥0.029 in 1Q 2021)

Northeast Pharmaceutical Group Co., Ltd. Approves the Profit Distribution for 2021

Full year 2021 earnings released: EPS: CN¥0.07 (vs CN¥0.01 in FY 2020)

Northeast Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for 2021

High number of new directors

Third quarter 2021 earnings released: CN¥0.026 loss per share (vs CN¥0.042 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.016 (vs CN¥0.063 in 2Q 2020)

Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend of A Shares, Payable on 27 May 2021

First quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.013 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.01 (vs CN¥0.13 in FY 2019)

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 17, 2021

New 90-day low: CN¥4.86

New 90-day low: CN¥5.03

New 90-day low: CN¥5.37

New 90-day low: CN¥5.39

Third quarter earnings released

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Jiangxi Fangda Steel Technology Co., Ltd. completed the acquisition of an additional 10% stake in Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) for approximately CNY 890 million.

Northeast Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 2 billion in funding from Joyvio Group Co., Ltd., Liaoning Fangda Group Industrial Co., Ltd., and other investors

First half earnings released

New 90-day high - CN¥6.15

New 90-day high - CN¥6.02

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media